TFE3 and neoplasm with perivascular epithelioid cell differentiation: Here, we report the first case of malignant gastrointestinal PEComa with <i>TFE3</i> rearrangement which has a response to the targeted therapy of an anti-VEGFR tyrosine kinase inhibitor (TKI), apatinib.